DGX

SEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · nonDerivative · entry 2

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,261

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $187.00 to $187.480. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001022079-25-000203 · wk-form4_1759264615.xml · nonDerivative · entry 1

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,344

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · derivative · entry 7

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 227

Underlying: Common Stock · 175 shares

Expires 2028-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 4

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,117

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $187.000 to $187.350. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 3

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,292

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · derivative · entry 6

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 402

Underlying: Common Stock · 28,288 shares

Expires 2028-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F5 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 19, 2019, the second on February 19, 2020 and the final on February 19, 2021.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 2

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,117

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F2 · price: This transaction was executed in multiple trades at prices ranging from $187.000 to $187.880. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001222679-25-000004 · wk-form4_1758832748.xml · nonDerivative · entry 1

PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,405

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000200 · wk-form4_1756153676.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,269

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000198 · wk-form4_1755808441.xml · derivative · entry 3

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,532 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F2 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023.

SEC source: 0001022079-25-000198 · wk-form4_1755808441.xml · nonDerivative · entry 2

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,244

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000198 · wk-form4_1755808441.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,776

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001497368-25-000007 · wk-form4_1755636429.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,244

F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001955217-25-000005 · wk-form4_1755293154.xml · nonDerivative · entry 1

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,338

F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted stock units.

F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

SEC source: 0001497368-25-000005 · wk-form4_1754685636.xml · derivative · entry 4

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,560 shares

Expires 2029-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F3 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.

SEC source: 0001497368-25-000005 · wk-form4_1754685636.xml · nonDerivative · entry 3

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,219

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

SEC source: 0001497368-25-000005 · wk-form4_1754685636.xml · nonDerivative · entry 2

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,185

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001497368-25-000005 · wk-form4_1754685636.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,745

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · nonDerivative · entry 7

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,450

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · derivative · entry 9

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,224 shares

Expires 2030-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · derivative · entry 8

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,045 shares

Expires 2029-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

F3 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · nonDerivative · entry 4

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,660

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · nonDerivative · entry 3

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,884

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · nonDerivative · entry 2

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,660

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000195 · wk-form4_1754080639.xml · nonDerivative · entry 1

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000186 · wk-form4_1753475235.xml · nonDerivative · entry 1

Lassiter Wright III · CIK 0001805909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,044

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000189 · wk-form4_1753475333.xml · nonDerivative · entry 1

SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,673

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000188 · wk-form4_1753475302.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,185

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.

SEC source: 0001022079-25-000187 · wk-form4_1753475272.xml · nonDerivative · entry 1

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,660

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the reporting person's last filing on Form 4.

SEC source: 0001022079-25-000185 · wk-form4_1753475203.xml · nonDerivative · entry 1

Gregg Vicky B · CIK 0001510304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,217

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000184 · wk-form4_1753475171.xml · nonDerivative · entry 1

DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,515

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000183 · wk-form4_1753475137.xml · nonDerivative · entry 1

CARTER ROBERT B · CIK 0001197607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,692

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000168 · wk-form4_1752783979.xml · nonDerivative · entry 1

SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,601

F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted stock units.

SEC source: 0001022079-25-000165 · wk-form4_1751487991.xml · derivative · entry 1

Lassiter Wright III · CIK 0001805909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 520.854

Underlying: Common Stock · 160 shares

Expires not disclosed

F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.

F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.

F2 · derivative.underlying_shares: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11.

SEC source: 0001022079-25-000166 · wk-form4_1751488046.xml · derivative · entry 1

RING TIMOTHY M · CIK 0001204666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,725.378

Underlying: Common Stock · 236 shares

Expires not disclosed

F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.

F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.

F2 · derivative.underlying_shares: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11.

SEC source: 0001022079-25-000144 · wk-form4_1747686084.xml · nonDerivative · entry 1

Lassiter Wright III · CIK 0001805909 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,037

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000150 · wk-form4_1747686272.xml · nonDerivative · entry 1

CARTER ROBERT B · CIK 0001197607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,685

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000149 · wk-form4_1747686237.xml · nonDerivative · entry 1

Diaz Luis · CIK 0001720081 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,054

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000148 · wk-form4_1747686206.xml · nonDerivative · entry 1

Gregg Vicky B · CIK 0001510304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,138

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000147 · wk-form4_1747686176.xml · nonDerivative · entry 1

Doi Tracey · CIK 0001527766 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,490

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000146 · wk-form4_1747686143.xml · nonDerivative · entry 1

MAIN TIMOTHY L · CIK 0001196744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,297

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000145 · wk-form4_1747686114.xml · nonDerivative · entry 1

MORRISON DENISE M · CIK 0001230166 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,742

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000143 · wk-form4_1747686052.xml · nonDerivative · entry 1

RING TIMOTHY M · CIK 0001204666 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,507

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000142 · wk-form4_1747686016.xml · nonDerivative · entry 1

PFEIFFER GARY M · CIK 0001127304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,669

F1 · security: Represents an award of restricted stock units.

SEC source: 0001022079-25-000132 · wk-form4_1747257144.xml · nonDerivative · entry 2

DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,498

F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000132 · wk-form4_1747257144.xml · nonDerivative · entry 1

DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,372

F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

SEC source: 0001022079-25-000129 · wk-form4_1746217961.xml · nonDerivative · entry 1

KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,612

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000130 · wk-form4_1746217999.xml · nonDerivative · entry 1

SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,451

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000128 · wk-form4_1746217917.xml · nonDerivative · entry 1

Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,087

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

SEC source: 0001022079-25-000127 · wk-form4_1746217881.xml · nonDerivative · entry 1

Gregg Vicky B · CIK 0001510304 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,935

F1 · shares: Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.